NATIONAL HARBOR, Md. (GenomeWeb) — At the annual meeting of the Association for Molecular Pathology here this week, attendees gathered for a question and answer session with US Food and Drug Administration officials Alberto Gutierrez and Elizabeth Mansfield, who fielded 45 minutes of queries on the scope and details of the FDA's draft guidance on the regulation of laboratory developed tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.